.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF13_TenofovirAlafenamide.TenofovirAlafenamide .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF13_TenofovirAlafenamide.TenofovirAlafenamide| name: | TenofovirAlafenamide |
| ATC code: | J05AF13 | route: | oral |
| n-compartments | 2 |
Tenofovir alafenamide is an antiretroviral prodrug of tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B in adults and adolescents. It has improved plasma stability and delivers the active drug at lower doses with reduced systemic toxicity compared to tenofovir disoproxil fumarate. Tenofovir alafenamide is approved and widely used today.
Pharmacokinetic parameters reported for healthy adult subjects after oral administration of tenofovir alafenamide 25 mg once daily.
Gunawardana, M, et al., & Baum, MM (2015). Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrobial agents and chemotherapy 59(7) 3913–3919. DOI:10.1128/AAC.00656-15 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25896688
Ray, AS, et al., & Hitchcock, MJ (2016). Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral research 125 63–70. DOI:10.1016/j.antiviral.2015.11.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26640223
Benítez-Gutiérrez, L, et al., & de Mendoza, C (2018). Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert review of clinical pharmacology 11(5) 507–517. DOI:10.1080/17512433.2018.1453805 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29595351